Comparison between MIBI-based radiopharmaceuticals for parathyroid scintigraphy: quantitative evaluation and...

Area of Science:

• Nuclear medicine
• Radiopharmacology

Background:

• Parathyroid scintigraphy is essential for hyperparathyroidism (HPT) diagnosis.
• 99mTc-methoxy-isobutyl-isonitrile (MIBI) is a key radiopharmaceutical for this procedure.
• Commercial MIBI agents (MediMIBI, TechneMIBI, Stamicis) exist, with choices often based on commercial factors despite potential performance differences.

Purpose of the Study:

• To compare quantitative scintigraphic data of MediMIBI, TechneMIBI, and Stamicis for personalized medicine in HPT.
• To assess the impact of clinical-laboratory data on image quality with these MIBI agents.

Main Methods:

• Retrospective analysis of 250 HPT patients undergoing parathyroid scintigraphy with MediMIBI, TechneMIBI, or Stamicis (Dec 2018-Oct 2020).
• Region of Interest (ROI) analysis for parathyroid uptake, background, and liver uptake.
• Evaluation of clinical-laboratory data (serum calcium, PTH, vitamin D, creatinine) and drug interferences.

Main Results:

• Statistically significant differences (p < 0.05) were observed in ROIs for parathyroid uptake, background, and hepatic dome among the three MIBI agents.
• No significant differences were found in other semi-quantitative parameters between the agents.
• Clinical-laboratory data did not influence the semi-quantitative parameters.

Conclusions:

• Emerging differences in semi-quantitative parameters exist among MIBI-based radiopharmaceuticals for parathyroid scintigraphy.
• These quantitative variations may account for observed differences in qualitative scintigraphic results.